In today’s Q3 2019 earnings report, Pledpharma reiterates its plan to deliver top-line results for the POLAR-A study in Q4 2020 (in-line with our expectation), but in the POALR-M trial, there has been a delay, meaning top-line results in Q2 2021 (we expected Q4 2020). The delay does not affect our view of the case in any major way, and we reiterate our positive stance on the stock following the Q3 report.